| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | |
|---|---|---|---|---|
| Acquired in-process research and development | - | - | 2,129,491.5* | |
| Grant revenue | 227,629 | - | - | |
| Research and development | 1,304,345 | 749,813 | 92,042.5* | |
| General and administrative | 1,326,676 | 1,533,926 | 931,954* | |
| Total operating expenses | 2,631,021 | 2,283,739 | 3,153,488 | |
| Loss from operations | -2,631,021 | -2,283,739 | -3,153,488* | |
| Interest income and other, net | 29,592 | 59,111 | 23,868* | |
| Loss from continuing operations | - | -2,224,628 | - | |
| Net loss | -2,373,800 | -2,224,628 | -3,129,620 | |
| Loss from continuing operation, total | - | -2,224,628 | - | |
| Loss from continuing operations attributable to common stockholders | - | -2,224,628 | -3,129,620 | |
| Basic EPS | -4.46 | -4.18 | -32.275 | |
| Diluted EPS | -4.46 | -4.18 | -32.275 | |
| Basic Average Shares | 531,968 | 531,968 | 96,967 | |
| Diluted Average Shares | 531,968 | 531,968 | 96,967 | |
Decoy Therapeutics Inc. (DCOY)
Decoy Therapeutics Inc. (DCOY)